Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: A multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the mayo phase II consortium and the cancer therapeutics research group
10.1200/JCO.2011.41.2395
Saved in:
Main Authors: | Yeo, W., Chung, H.C., Chan, S.L., Wang, L.Z., Lim, R., Picus, J., Boyer, M., Mo, F.K.F., Koh, J., Rha, S.Y., Hui, E.P., Jeung, H.C., Roh, J.K., Yu, S.C.H., To, K.F., Tao, Q., Ma, B.B., Chan, A.W.H., Tong, J.H.M., Erlichman, C., Chan, A.T.C., Goh, B.C. |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Article |
Published: |
2014
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/115095 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma
by: Chuah, B., et al.
Published: (2016) -
Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: A multicenter phase II study by the cancer therapeutic research group
by: Ho, W.M., et al.
Published: (2016) -
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma
by: Toh, H.C., et al.
Published: (2014) -
Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
by: Yeo, W., et al.
Published: (2011) -
A phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma
by: Choo, S. P., et al.
Published: (2013)